The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Read More
Roche’s Alecensa has won NICE backing as a treatment for a rare type of lung cancer, over-turning a prior decision to reject NHS funding for the drug.
Read More
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s Alecensa as a first-line treatment for lung cancer.
Read More
Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.
Read More
Roche group Genentech says its application to expand the use of Alecensa to include first-line treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) has been approved by US regulators.
Read More
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended just one generic medicine for approval at its October meeting.
Read More
UK patients with a rare form of lung cancer will be able to access Roche’s Alecensa without the need for prior chemotherapy before official approval is obtained, following its inclusion in the country’s Early Access to Medicines Scheme.
Read More
Roche has presented late-stage data showing that its Alecensa was superior to Pfizer’s Xalkori on progression-free survival in patients with a specific type of lung cancer.
Read More
European regulators have given the go-ahead to Roche’s Alecensa as a treatment for people with previously treated ALK-positive non-small cell lung cancer (NSCLC).
Read More
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has backed seven new medicines for approval at its December meeting, bringing the total number recommended during the year to 81, dropping from 2015’s tally of 93.
Read More
